Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Voltaren
Drug ID BADD_D02367
Description Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin].[A180796] The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the FDA in July 1988 under the trade name Voltaren, marketed by Novartis (previously Ciba-Geigy).[L7360]
Indications and Usage For the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code D11AX18; M01AB05; M02AA15; S01BC03
DrugBank ID DB00586
KEGG ID D00904
MeSH ID D004008
PubChem ID 5018304
TTD Drug ID D0TG1H
NDC Product Code 50090-2787; 55700-675; 58602-603; 70518-0871; 11014-0415; 55700-735; 57896-142; 58602-602; 65162-911; 68788-7270; 17856-0833; 69344-203; 76420-012; 62512-0051; 42291-256; 58602-601; 71335-0371; 80425-0056; 50090-3316; 11014-0416; 63187-762; 69238-2053; 0378-8750; 45865-986; 50268-237; 70518-1333; 50090-4621; 69344-204; 73480-242; 48589-0002; 65162-833
Synonyms Diclofenac | Diclophenac | Dicrofenac | Dichlofenal | Diclofenac Sodium | Sodium Diclofenac | Diclofenac, Sodium | Diclonate P | Feloran | Voltarol | Novapirina | Orthofen | Ortofen | Orthophen | SR-38 | SR 38 | SR38 | Voltaren | Diclofenac Potassium | GP-45,840 | GP 45,840 | GP45,840
Chemical Information
Molecular Formula C14H10Cl2NNaO2
CAS Registry Number 15307-79-6
SMILES C1=CC=C(C(=C1)CC(=O)[O-])NC2=C(C=CC=C2Cl)Cl.[Na+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HepatotoxicityCytochrome P450 2C9P11712T1924410027798; 10027801; 10064567
HepatotoxicityCytochrome P450 3A4P08684T3784810027798; 10027801; 10064567
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemorrhage24.07.01.002--Not Available
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
Vasodilation procedure25.03.01.001--Not Available
Angiopathy24.03.02.007--Not Available
Urine output increased13.13.03.002--Not Available
Gastric pH decreased13.05.04.001--Not Available
Induration08.01.03.020--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Cardiac disorder02.01.01.003--Not Available
Infestation23.09.05.001; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Oesophageal disorder07.11.02.001--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Corneal disorder06.08.01.004--Not Available
Gastrointestinal ulcer07.04.04.002--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Lacrimal disorder06.08.02.005--Not Available
Blood disorder01.05.01.004--Not Available
Psychotic disorder19.03.01.002--
Pulmonary function test decreased13.19.01.001--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.010--Not Available
Cystitis noninfective20.03.02.001--
Application site induration12.07.01.015; 08.02.01.014--Not Available
Intestinal diaphragm disease07.13.01.011--Not Available
Procedural pain12.02.05.007; 08.01.08.009--Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages